EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Orphan drugs: trends and issues in drug development

Proteesh Rana, Shalini Chawla

Journal of Basic and Clinical Physiology and Pharmacology · 25.09.2018 · 29 (5) · 437-446

DOI: 10.1515/jbcpp-2017-0206 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, online erschienen am 12.04.2018. Verfasst von Proteesh Rana und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Officer,Department of Pharmacology, Dr. Ram Manohar Lohia Hospital and Post Graduate Institute of Medical Sciences and Research, New Delhi, I…. Hauptthemen laut MEDLINE: Orphan Drug Production. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research in rare diseases has contributed substantially toward the current understanding in the pathophysiology of the common diseases. However, medical needs of patients with rare diseases have always been neglected by the society and pharmaceutical industries based on their small numbers and unprofitability. The Orphan Drug Act (1983) was the first serious attempt to address the unmet medical needs for patients with rare diseases and to provide impetus for the pharmaceutical industry to promote orphan drug development. The process of drug development for rare diseases is no different from common diseases but involves significant cost and infrastructure. Further, certain aspect of drug research may not be feasible for the rare diseases. The drug-approving authority must exercise their scientific judgment and ensure due flexibility while evaluating data at various stages of orphan drug development. The emergence of patent cliff combined with the government incentives led the pharmaceutical industry to realize the good commercial prospects in developing an orphan drug despite the small market size. Indeed, many drugs that were given orphan designation ended up being blockbusters. The orphan drug market is projected to reach $178 billion by 2020, and the prospects of research and development in rare diseases appears to be quite promising and rewarding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionDrug DevelopmentDrug DiscoveryDrug and Narcotic ControlResearch

Stichwörter der Autor:innen

GleevecODAorphan drugrare diseases

Autor:innen und Institutionen

  • Medical Officer,Department of Pharmacology, Dr. Ram Manohar Lohia Hospital and Post Graduate Institute of Medical Sciences and Research, New Delhi, India.
  • Department of Pharmacology, Maulana Azad Medical College, New Delhi, India.

Zitieren

APA

Rana, P., & Chawla, S. (2018). Orphan drugs: trends and issues in drug development. Journal of Basic and Clinical Physiology and Pharmacology, 29(5), 437-446. https://doi.org/10.1515/jbcpp-2017-0206

Vancouver

Rana P, Chawla S. Orphan drugs: trends and issues in drug development. Journal of Basic and Clinical Physiology and Pharmacology. 2018;29(5):437-446. doi:10.1515/jbcpp-2017-0206

BibTeX
@article{Rana2018,
  author = {Rana, Proteesh and Chawla, Shalini},
  title = {Orphan drugs: trends and issues in drug development},
  journal = {Journal of Basic and Clinical Physiology and Pharmacology},
  year = {2018},
  volume = {29},
  number = {5},
  pages = {437--446},
  doi = {10.1515/jbcpp-2017-0206}
}
Kostenlos starten →